Fortress Biotech, Inc. - Common Stock (FBIO)

Competitors to Fortress Biotech, Inc. - Common Stock (FBIO)

Amgen Inc. 

Amgen is a global leader in biotechnology that focuses on developing therapies for serious illnesses, potentially competing directly with Fortress Biotech in the development and commercialization of novel therapies. Both companies aim to introduce innovative drugs, but Amgen has a more extensive pipeline and significant resources, allowing them to be a dominant force with established market presence and regulatory experience.

Bluebird Bio, Inc. 

Bluebird Bio specializes in gene therapy for genetic diseases and cancer, positioning itself in the more cutting-edge segment of biotechnology in which Fortress Biotech also operates. While Bluebird Bio has garnered attention and investments because of its innovative approaches, Fortress’s strategy of leveraging partnerships and collaborations could allow it to catch up rapidly by accelerating its product development timeline.

Catalent, Inc. 

Catalent is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, including biologics and gene therapies. While Fortress Biotech focuses on drug development and commercialization, Catalent's role as a service provider creates a competitive relationship with Fortress as both entities work at different stages of the pharmaceutical pipeline. Catalent's extensive scale and technical capabilities give it a competitive advantage in terms of operational capacity.

Gilead Sciences, Inc. 

Gilead is renowned for its antiviral medications and has a strong focus on therapeutic areas similar to those targeted by Fortress Biotech. The competition arises in the quest for new treatments and clinical advancements. Gilead's entrenched position in the market and considerable R&D investment provide a competitive edge in bringing drugs to market faster and on a larger scale.

Salix Pharmaceuticals

Salix focuses on gastrointestinal diseases and brings specialized products to the market, which overlaps with some of Fortress Biotech's therapeutic areas. While Salix holds a competitive niche due to its targeted approach, Fortress Biotech's broader strategy in licensing and acquiring various biotech assets gives it a diversified portfolio that can appeal to a wider range of unmet medical needs.